Sandoz stock surges 4.4% on bold biosimilar plan and capacity investment

Sandoz stock advanced 4.4% to CHF 71.22 after the Basel-based generics and biosimilars specialist hosted its Capital Markets Day, where executives presented a bold long-term strategy that sparked enthusiasm among investors.

At the heart of the event was the so-called Bio100 initiative, which seeks to widen Sandoz’s biosimilar lineup from 13 approved products to more than 100 by 2040, while lifting the company’s capture of biosimilar loss-of-exclusivity value to roughly 80% by 2035, versus approximately 50% now.

In addition, the management outlined a clear multi-year financial plan for 2025–2030, targeting annual net sales growth of mid-to-high single digits and a core EBITDA margin of 25–27% by the end of the decade. Further out, Sandoz aims to more than double net sales and achieve a core EBITDA margin above 30% by 2035.

To give the strategy additional weight, Sandoz announced it would invest in a new biosimilar drug substance manufacturing plant in Ljubljana, Slovenia, a concrete signal that capital allocation supports the Bio100 roadmap. CEO Richard Saynor led the meeting, characterizing the current period as a 'golden decade' for biosimilars.

The stock’s advance ran against a cautious tone in global markets, with U.S. indices trading lower — the S&P 500 fell 0.4% and the Dow Jones dropped 0.9%. That divergence underscores that Sandoz’s move was driven entirely by company-specific news, not macroeconomic momentum.

Analyst positioning ahead of the event had been predominantly supportive, with several institutions maintaining Overweight-equivalent ratings and price objectives of CHF 75–80. This favourable backdrop likely magnified the market’s upbeat assessment of the disclosures.

Overall, the combination of a transformative biosimilar ambition, quantified margin and revenue goals, and a concrete manufacturing investment provided investors with sufficient visibility to lift the shares toward their 52-week high of CHF 75.90. On the day, the stock peaked at CHF 71.48, a striking performance given the risk-off tone elsewhere.

This article was compiled with the aid of AI and reviewed by an editor before publication. For further information, please refer to our Terms & Conditions.